|

IDE-161 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • IDEAYA Biosciences1

Indications

  • Advanced or Metastatic Solid Tumors1
  • Head and Neck Cancers1
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
  • Endometrial Cancer1
  • NSCLC1

Phoenix, Arizona1 trial

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

HonorHealth Research Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.